Alyeska Investment Group, L.P. Apellis Pharmaceuticals, Inc. Transaction History
Alyeska Investment Group, L.P.
- $23.4 Billion
- Q1 2025
A detailed history of Alyeska Investment Group, L.P. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 150,000 shares of APLS stock, worth $2.82 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
150,000Holding current value
$2.82 Million% of portfolio
0.01%Shares
2 transactions
Others Institutions Holding APLS
# of Institutions
295Shares Held
124MCall Options Held
921KPut Options Held
761K-
Wellington Management Group LLP Boston, MA12.3MShares$232 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.2MShares$230 Million4.32% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$224 Million20.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$191 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.63MShares$181 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.07B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...